Abstract:150 Objectives: Phosphodiesterase-10 (PDE10A), one of the dual-substrate specific enzymes of PDE superfamily, represents a potential biomarker for neurodegenerative and neuropsychiatric diseases. However, a number of outcomes in clinical trials with PDE10A inhibitors so far are disappointing. Imaging of PDE10A in vivo with effective PET tracers would considerably accelerate drug discovery and clinical application for disease diagnosis. Here we report a novel PDE10A radioligand 18F-P10A1910, including the radiolabeling, ex vivo biodistribution (bioD) and metabolism, and preliminary PET imaging on rats and rhesus by dose-dependent blocking study for evaluating specificity and receptor occupancy. Methods: The PDE10A inhibitor P10A1910 and the SCIDY precursor Pre-1 were synthesized according to the literature [1,2,3].The binding affinity and selectivity of P10A1910 to PDE10A and other fourteen PDE family enzymes were examined in vitro. The radiolabeling of 18F-P10A1910 was realized by one-step 18F incorporation via the commercially automatic GE FX2 N module. Pharmacokinetic properties were tested via bioD studies in ICR mice. In addition, dynamic PET imaging studies of 18F-P10A1910 were conducted on SD rats and rhesus for evaluating in vivo brain penetration, specificity, and target engagement. Results: The inhibitor P10A1910 and SCIDY precursor Pre-1 were synthesized in 4-5 steps with 11% and 8% overall yields, respectively. P10A1910 exhibited good binding affinity for PDE10A (IC50 = 2.05 nM) and excellent selectivity over other PDE subtypes.18F-P10A1910 was produced from Pre-1 in 15 ± 5% n.d.c RCYs (n = 30) in less than 70 min from EOB with more than 99% radiochemical purity and around 3 Ci/μmol molar radioactivity. The radioactivity at 5 min post-injection was mainly accumulated in the liver and small intestine (more than 50 %ID/g), which indicated that the excretion of radiotracer occurred primarily through the hepatobiliary clearance. Blood clearance of 18F-P10A1910 was fairly fast (activity ratio is more than 20). No obvious bone uptake was observed. PET imaging on rats showed a high brain uptake (SUVpeak = 1.5 SUV at 2 min post-injection) and a rapid washout (SUV1.4min/60 min = 3). Furthermore, the pre-blocking and chase-blocking PET study on rats demonstrated the binding of 18F-P10A1910 to PDE10A was reversible and specific. Metabolite analysis demonstrated the first-class stability of 18F-P10A-1910 in rat brain (more than 96% of intact tracer retained at 60 min post injection). Furthermore, blocking experiments with escalating doses of PF-02545920 revealed a dose-dependent decrease of striatal tracer uptake in the rhesus brain. Target engagement studies unveiled that dose of 2.09 μmol/kg PF-02545920 occupied 50% of the target receptor. In addition, our results showed that the recently reported therapeutically active PF-02545920 doses of 0.21 mg/kg and 1.33 mg/kg occupy 22% and 63% of PDE10A in the monkey brain, respectively. Accordingly, our results imply that a relatively low receptor occupancy already elicits neuroprotective activity. Further, we hypothesize that higher doses might lead to improved therapeutic efficacy by occupying a higher degree of PDE10A. These results underline the potential utility of 18F-P10A1910 for in vivo visualization and quantification of PDE10A-based target engagement. Conclusion: Based on the designed SPIAd precursor Pre-1, we successfully synthesized a novel PDE10A radioligand 18F-P10A1910 in good radiochemical yields with high purities and molar activities. In vitro binding affinity and selectivity testing, ex vivo bioD studies in mice, as well as dynamic neuroPET imaging on rats and rhesus were performed, and the results demonstrated 18F-P10A1910 is a promising candidate with adequate brain penetration, good stability and excellent specificity.

Analysis of (R)- and (S)-[11C]rolipram Kinetics in Canine Myocardium for the Evaluation of Phosphodiesterase-4 with PET

First-in-Human Evaluation Of18f-Pf-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4B

Radiosynthesis and Preclinical Evaluation of an 18F-Labeled Triazolopyridopyrazine-Based Inhibitor for Neuroimaging of the Phosphodiesterase 2A (PDE2A)

Radiosynthesis and evaluation of acetamidobenzoxazolone based radioligand [C-11]N '-MPB for visualization of 18 kDa TSPO in brain

Radioligands for imaging myocardial α- and β-adrenoceptors

Easily Automated Radiosynthesis of [18F]P10A-1910 and Its Clinical Translation to Quantify Phosphodiesterase 10A in Human Brain.

Spirocyclic Iodonium Ylide (Scidy)-Mediated Radiofluorination of a Novel PDE10A PET Ligand for Neuroimaging

Asymmetric synthesis and preliminary evaluation of (R)- and (S)-[11C]bisoprolol, a putative beta1-selective adrenoceptor radioligand

In Vivo Characterization of Two 18F-Labeled PDE10A PET Radioligands in Nonhuman Primate Brains.

Preclinical in vitro and in vivo evaluation of [11C]ORM-13070 as PET ligand for alpha-2C adrenergic receptor occupancy using PET imaging in non-human primates

[18F]F13640: a selective agonist PET radiopharmaceutical for imaging functional 5-HT1A receptors in humans

Imaging dopamine release with Positron Emission Tomography (PET) and (11)C-raclopride in freely moving animals

Characterization of a Novel M4 PAM PET Radioligand [11C]PF06885190 in Nonhuman Primates (NHP)

Development and Preliminary Evaluation of an Aryl 18F-Labeled PET Tracer for Imaging PDE10A

82Rb-PET is feasible in rodent AMI model after positron range correction

Comparison of Two Pde10a Radiotracers, [11c]tz1964b and [18f]mni659 in the Brains of Non-Human Primates

Radiosynthesis and ex vivo evaluation of [11C]-SIB-1553A as a PET radiotracer for beta4 selective subtype nicotinic acetylcholine receptor

Development and evaluation of novel PET tracers for imaging cannabinoid receptor type 2 in brain

Simplified estimation of binding parameters based on image-derived reference tissue models for dopamine transporter bindings in non-human primates using [18F]FE-PE2I and PET

Synthesis and evaluation of two new candidate high-affinity full agonist PET radioligands for imaging 5-HT1B receptors

Synthesis and evaluation of a novel PET ligand, a GSK'963 analog, aiming at autoradiography and imaging of the receptor interacting protein kinase 1 in the brain